TY  - JOUR
AU  - Lopez-Millan, Belen
AU  - Diaz de la Guardia, Rafael
AU  - Roca-Ho, Heleia
AU  - Anguita, Eduardo
AU  - Islam, Abul B M M K
AU  - Romero-Moya, Damia
AU  - Prieto, Cristina
AU  - Gutierrez-Agüera, Francisco
AU  - Bejarano-Garcia, Jose Antonio
AU  - Perez-Simon, Jose Antonio
AU  - Costales, Paula
AU  - Rovira, Montse
AU  - Marín, Pedro
AU  - Menendez, Silvia
AU  - Iglesias, Mar
AU  - Fuster, Jose Luis
AU  - Urbano-Ispizua, Alvaro
AU  - Anjos-Afonso, Fernando
AU  - Bueno, Clara
AU  - Menendez, Pablo
PY  - 2018
DO  - 10.1080/2162402X.2018.1477460
SN  - 2162-4011
UR  - http://hdl.handle.net/10668/12963
T2  - Oncoimmunology
AB  - Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and the BM stroma is a major...
LA  - en
KW  - AML
KW  - AraC
KW  - BM-MSC
KW  - IMiDs
KW  - Idarubicin
KW  - lenalidomide
KW  - pomalidomide
KW  - xenografts
TI  - IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML.
TY  - research article
VL  - 7
ER  -